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Trial DesignsReduced duration of dual antiplatelet therapy
using an improved drug-eluting stent for
percutaneous coronary intervention of the left
mainartery inareal-world,all-comerpopulation:
Rationale and study design of the prospective
randomizedmulticenter IDEAL-LM trial
Miguel E. Lemmert, MD, PhD, Keith Oldroyd, MB, ChB, MD, Paul Barragan, MD, Maciej Lesiak, MD,
Robert A. Byrne, MB, BCh, PhD, Evgeny Merkulov, MD, Joost Daemen, MD, PhD, Yoshinobu Onuma, MD, PhD,
Karen Witberg, CCRN, and Robert-Jan van Geuns, MD, PhD Rotterdam, the NetherlandsBackground Continuous improvements in stent technology make percutaneous coronary intervention (PCI) a potential
alternative to surgery in selected patients with unprotected left main coronary artery (uLMCA) disease. The optimal duration of
dual antiplatelet therapy (DAPT) in these patients remains undetermined, and in addition, new stent designs using a
bioabsorbable polymer might allow shorter duration of DAPT.
Study design IDEAL-LM is a prospective, randomized, multicenter study that will enroll 818 patients undergoing uLMCA PCI.
Patientswill be randomized in a1:1 fashion to intravascular ultrasound-guided PCIwith the novel everolimus-eluting platinum-chromium
Synergy stent with a biodegradable polymer (Boston Scientific, Natick, MA) followed by 4 months of DAPT or the everolimus-eluting
cobalt-chromium Xience stent (Abbott Vascular, Santa Clara, CA) followed by 12 months of DAPT. The total follow-up period will be 5
years. A subset of 100 patients will undergo optical coherence tomography at 3 months.
End points The primary end point will be major adverse cardiovascular events (composite of all-cause mortality,
myocardial infarction, and ischemia-driven target vessel revascularization) at 2 years. Secondary end points will consist of the
individual components of the primary end point, procedural success, a device-oriented composite end point, stent thrombosis
as per Academic Research Consortium criteria, and bleeding as per Bleeding Academic Research Consortium criteria.
Summary IDEAL-LM is designed to assess the safety and efficacy of the novel Synergy stent followed by 4 months of
DAPT vs the Xience stent followed by 12 months of DAPT in patients undergoing uLMCA PCI. The study will provide novel
insights regarding optimal treatment strategy for patients undergoing PCI of uLMCA disease (www.clinicaltrials.gov, NCT
02303717). (Am Heart J 2017;187:104-111.)Patients with a significant lesion in an unprotected left
main coronary artery (uLMCA) benefit from revasculari-
zation and coronary artery bypass graft (CABG) surgery
has traditionally been the preferred treatment.1 However,
in recent years, percutaneous coronary intervention (PCI)rom the and Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands.
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hhas emerged as a potential alternative to CABG. Recent trials
showed comparable rates of major adverse cardiac and
cerebrovascular events after 1 to 2 years between patients
withuLMCA lesions, treatedwith either PCI orCABG.2-4 This
also holds true for overall event rates after 5 years of
follow-up, albeit with a higher need for repeat revascular-
ization after PCI.5,6 Consequently, current international
guidelines recommend PCI as an acceptable treatment
option for selected patients with uLMCA disease.7-9
Recently, the NOBLE trial evaluated CABG vs PCI as
treatment of uLMCA lesions and suggested a superior
5-year outcome for CABG, owing to higher rates of
nonprocedural myocardial infarction (MI), repeat revas-
cularizations, and, although unexplained, ischemic
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coronary stents used in the NOBLE trial were
first -generation drug-eluting stents (DES) and
biolimus-eluting stents. Second-generation drug-eluting
stents, in particular everolimus-eluting stents, have been
shown to reduce rates of repeat revascularization.11 Indeed,
another recent trial, the EXCEL trial, almost exclusively used
everolimus-eluting stents in uLMCA lesions and showed
noninferiority of PCI to CABG after 3 years in patients
deemed eligible for both PCI and CABG.12
Stent technology
Since the introduction of bare-metal stents, stent
platform technology has continued to evolve with
progressive improvements in deliverability, conformabil-
ity, and both radial and longitudinal strength.13,14 With
the advent of DES, potent antiproliferative agents were
added to reduce neointimal proliferation. These were
usually embedded in polymers to control drug release,
and over time, these polymers have become increasingly
biocompatible with the aim of reducing inflammation
and accelerating healing.14 The metallic materials used
for the stent platform have also undergone changes going
from stainless steel and cobalt-chromium in the
earlier-generation stents to platinum-chromium in the
later-generation DES, with advantages including increased
radial strength, fracture resistance, and radio-opacity.15,16
Stent struts have become thinner, which reduces flow
disturbances and improves endothelial coverage.17
The SYNERGY everolimus-eluting stent (Boston Scientific,
Natick, MA) is an example of a latest-generation DES and is
based on a platinum-chromium platform with a strut
thickness of 74 μm. In contrast to the commonly used
durable polymers, it has a biodegradable polymer applied
only on the abluminal side of the stent and which is fully
absorbed within 3 to 4 months. These changes were
introduced to improve early endothelialization of the stent
struts, accelerate vessel healing, and reduce the risk of both
stent thrombosis and restenosis. In previous studies, this
device has been shown to have a very low incidence of
reintervention with excellent clinical outcomes.18-20
In uLMCA PCI, there are potentially large differences
between proximal and distal vessel diameters, and so the
overexpansion capability of the stent is another impor-
tant factor influencing outcomes. Unfortunately, manu-
facturers often do not specify maximal overexpansion
capabilities. In vitro testing of the overexpansion
capabilities of commonly used stent platforms has
shown that the 4.0-mm Xience Prime stent (Abbott
Vascular, Santa Clara, CA) can be maximally expanded to
5.6 mm using a 6.0-mm balloon.21 However, this is at the
expense of stent structure deformation with potentially
adverse clinical effects. In contrast to this, the manufac-
turer of the Synergy stent specifies an overexpansion
capability to 5.75 mm for a 4.0-mm stent without stentdeformation, which could be a beneficial feature for
uLMCA PCI.
Duration of dual antiplatelet therapy
Another important factor influencing long-term outcome
after PCI is the durationof dual antiplatelet therapy (DAPT). In
previous studies using first-generation DES, a significant
association was observed between discontinuation of DAPT
and the occurrence of thrombotic events in the first 6 to
12 months after the procedure. Based on these findings,
current European Society of Cardiology (ESC) guidelines
recommend6 to 12 months ofDAPT afterDES implantation.7
However, recent randomized trials using second-generation
everolimus- or zotarolimus-eluting DES demonstrated no
reduction in stent-related ischemic events with prolonged
DAPT but an excess of bleeding complications.22,23 In the
Prolonging Dual Antiplatelet Treatment After Grading
Stent-Induced Intima Hyperplasia (PRODIGY) study, the
primary outcome (all-cause mortality, MI, or stroke) was
similar for patients randomized to 6 or 24 months of DAPT
therapy.23 The Optimized Duration of Clopidogrel Therapy
Following Treatment With the Zotarolimus-Eluting Stent in
Real-World Clinical Practice (OPTIMIZE) trial showed that in
patients with stable coronary artery disease or low-risk acute
coronary syndrome (ACS) treated with zotarolimus-eluting
stents, 3 months of DAPT was noninferior to 12 months
with regard to net clinical adverse events and cerebral
events, that is, without significantly increasing the risk of
stent thrombosis.24 These findings were confirmed by
meta-analyses, which included the PRODIGY and OPTIMIZE
trials.25,26 This suggests that DAPT for 3 to 6 months could be
safe after implantation of second-generationDES, even in some
patients with recent ACS.
Study aims
Stent failure in the uLMCA is potentially catastrophic
emphasizing the necessity of identifying the best available
stent and the optimal duration of DAPT after PCI in this
location. Complete apposition and early endothelial
coverage of the stent struts should allow for a shorter
duration of DAPT. Accordingly, the IDEAL-LM study will
evaluate the SYNERGY stent (Boston Scientific) followed
by 4 months of DAPT to the current standard of care
XIENCE stent (Abbott Vascular) followed by 12 months
of DAPT with regard to noninferiority for safety and
efficacy end points in patients undergoing uLMCA PCI.
Study design
IDEAL-LM is a prospective, randomized, multicenter
(34 sites in France, the Netherlands, Poland, Russia,
Germany, and United Kingdom) study in patients with
uLMCA disease and an indication for coronary artery
revascularization who have been discussed in the local
Heart Team and accepted for PCI. Patients are
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(study cohort) or to the XIENCE stent arm (control
cohort). Randomization is performed using Web-based
software (e-DREAM system) with random blocks accord-
ing to center. Randomization occurs at the time of the
index procedure before PCI. Dual antiplatelet therapy
will be stopped after 4 months in the study cohort,
whereas in the control cohort, it will be continued for
12 months. The use of intravascular ultrasound (IVUS) to
optimize stent deployment is strongly encouraged in both
groups in accordance with the most recent ESC
guidelines.8 A subgroup of 100 patients will have
angiographic follow-up with optical coherence tomogra-
phy (OCT) 3 months after treatment. The study flowchart
is depicted in Figure.
This study is investigator initiated and has been
designed by the Glasgow Jubilee National Hospital
(Glasgow, Scotland) and the Thoraxcenter Rotterdam
(Erasmus Medical Center, Rotterdam, the Netherlands).
The study was approved by local institutional review
boards and adheres to the principles of the Declaration of
Helsinki and Good Clinical Practice. The study is
registered on www.clinicaltrials.gov NCT02303717.
Study objectives and end points
The primary objective is to establish the noninferiority of
the SYNERGY stent relative to the XIENCE stent for
prevention of the composite primary end point of major
adverse cardiac events (MACE). Amajor secondary objective
is to compare the outcomes of both patient groups with the
uLMCA cohort from the SYNTAX trial, thereby allowing a
comparison of outcomes with contemporary stent technol-
ogy to those with first-generation permanent
paclitaxel-eluting polymer DES.2,27
Primary end points. Both the primary and secondary
end points will be adjudicated by an independent and
blinded clinical end point committee (CEC). The primary
end point is the rate of MACE, which is a composite end
point of death from any cause, MI, or ischemia-driven
target vessel revascularization (TVR), at 2 years after the
PCI procedure.
Secondary end points. The secondary end points
consist of the individual components of the primary end
point; procedural success (attainment of b30% residual
stenosis of the target lesion and no in-hospital
device-oriented composite end points defined as cardiac
death, MI not clearly attributable to a nontreated vessel,
and clinically indicated target lesion revascularization);
device-oriented composite end point and its individual
components at 1 month, 6 months, and annually up to
3 years; stent thrombosis according to the Academic
Research Consortium definition at all time points28; the
composite of Bleeding Academic Research Consortium
(BARC) 3 or 5 at 24 months according to the BARC
definition29; and the individual bleeding events (BARC 1,
2, 3, 4, and 5) according to the BARC definition29;Secondary invasive end points consist of OCT end
points. The primary OCT end point will be the Healing
Score. This is a weighted index assigning points to 4
parameters: presence of filling defect (4 points), presence
of both malapposed and uncovered struts (3 points),
presence of uncovered struts alone (2 points), and
presence of malapposition alone (1 point). Secondary
OCT end points will be percentage of uncovered struts,
percentage of malapposed struts, lumen area, lumen
diameter, minimal lumen diameter, scaffold area, incom-
plete stent apposition area, mean prolapse area, number
of frames with dissection, calculated stent length,
malapposition distance, and mean thrombus area.
Study population
The local Heart Team consisting of an interventional
cardiologist and a cardiac surgeon assesses patients for
indication of revascularization in accordance with ESC
guidelines.8 Patients with a visual uLMCA stenosis of 50%
to 90% and (non)invasive evidence of hemodynamic
significance or N90% or a stenosis were eligible. The
revascularization strategy in patients should be deter-
mined early by the Heart Team based on the patient's
clinical status, as well as the severity and distribution of
the coronary artery disease (Syntax Score) and the
characteristics of the lesion.8 The complete inclusion
and exclusion criteria are shown in Table 1. There are no
exclusions based on either the number of non–left main
lesions or the Syntax Score.
Study stents
Synergy everolimus-eluting platinum-chromium
stent. The Synergy stent has a platinum-chromium
platform with a strut thickness of 74 μm and a radial
strength higher than cobalt-chromium and stainless steel
platforms.15,16 This stent is coated on the abluminal side
with a biodegradable poly(DL-lactide-coglycolide) layer
which is hydrolyzed to carbon dioxide and water over a
period of 120 days. This polymer is mixed with an
everolimus dose that is similar to that of Xience stents
(1 μg/mm2) and that is released over a period of 90 days.
The stent received Conformité Européenne mark on
October 31, 2012. The Synergy stent is manufactured by
Boston Scientific and is available in sizes of 2.25, 2.5, 2.75,
3.0, 3.5, 3.5, and 4.0 mm and in lengths of 8, 12, 16, 20,
24, 28, 32, and 38 mm. Compared with the Xience stents,
there are no specific deployment requirements for the
Synergy stent. The Synergy stent itself is also the subject
of registered currently recruiting trials such as EVOLVE
sho r t DAPT (NCT026054 47 ) a nd S EN IOR
(NCT02099617), which will provide further data on
clinical outcomes.
Xience everolimus-eluting cobalt-chromium
stent. The Xience everolimus-eluting cobalt-chromium
stent platform has a strut thickness of 81 μm and consists
of 3 types: Xience V, Xience Prime, and Xience Xpedition.
Figure
Study flow diagram. DOCE indicates device-oriented composite end point; ST, stent thrombosis.
Lemmert et al 107
American Heart Journal
Volume 187, Number 0The stent is coated with a formulation containing
everolimus embedded in a nonerodible polymer. The
polymer is loaded with 1 μg/mm2 of everolimus with a
maximumnominal drug content of 232 μg. All Xience stent
systems use an identical stent and stent-contacting balloon
materials and identical drug-coating formulations and
drug-dosing densities. The Xience stent is manufactured
by Abbott Vascular and is available in sizes of 2.25, 2.5,2.75, 3.0, 3.25, 3.5, and 4.0 mm and in lengths of 8, 12, 15,
18, 23, 28, 33, and 38 mm.
Study drugs
Preprocedural and periprocedural medication.
Patients will be treated with anticoagulation therapy
according to local hospital practice. In case of patients
presenting with ACS, the following periprocedural
Table 1. Inclusion and exclusion criteria
Inclusion criteria
1. Patient has an indication for revascularization of the LMCA in
accordance with ESC guidelines.
2. Patient has been discussed in the Heart Team with the cardiac surgeon
before PCI, after which patient is accepted for PCI.
3. Patient's age is at least 18 y.
4. Patient understands and accepts the meaning and aims of the study and
is willing to provide written informed consent.
5. Patient is willing to comply with specified follow-up evaluation and can
be contacted by telephone.
Exclusion criteria
1. Patient is not able to receive antiplatelet treatment due to
contraindications.
2. Patient has a known allergy to acetylsalicylic acid, clopidogrel,
prasugrel, or ticagrelor.
3. Patient is in cardiogenic shock at the time of treatment.
4. Patient had an ST-elevation MI within the 5 d before treatment.
5. Patient has planned surgery within 12 mo after treatment.
6. Patient has a history of bleeding diathesis or active major bleedings.
7. Patient had surgery within 15 d before treatment.
8. Patient participates in other trial, which did not yet reach its primary end
point.
9. Patient has a life expectancy of b12 mo.
10. Patient has a hypersensitivity or contraindication to everolimus or
structurally related compounds, cobalt, chromium, nickel, tungsten,
acrylic, and fluoropolymers.
11. Patient is female with childbearing potential not taking adequate
contraceptives or is currently breastfeeding.
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previously on aspirin treatment) and either clopidogrel
300-600 mg or ticagrelor 180 mg or prasugrel 60 mg.
Postprocedural medication. For the Synergy stent
group, the duration of DAPT will be 4 months, which is
the time required for the polymer to be resorbed, and for
the Xience stent group, the duration of DAPT will be
12 months. In patients on long-term oral anticoagulation
due to a preexisting condition (eg, atrial fibrillation), the
duration of triple therapy will be 4 months for the
Synergy stent group and 6 months for the Xience stent
group,30 but the treating physician is allowed to reduce
this time if the patient is at high risk for bleeding.
Study procedures
Pre-PCI and PCI procedure. Eligible patients will
receive oral and written information concerning the study.
Written and signed informed consent is required before any
study-specific procedure. Patients will undergo standard
coronary angiography to identify the target lesion. Treat-
ment of other lesions is allowed and the treatment order is at
the operator's discretion, but it is advised to use the same
stent type as the study stent. Usual standards of care will be
followed when performing the procedure. If a staged
procedure is planned, treatment of the non–target vessel
should be performed within 30 days, again preferably using
the same stent type as the study stent.
Predilatation of the target lesion is recommended but
left to the discretion of the operator. Standard stentingprocedures will be performed according to the local routine
practice. For LMCA bifurcation lesions, treatment strategy is
per operator discretion. Provisional stenting with side
branch opening is the preferred option, but 2-stent
approaches (T-stenting, TAP, Culotte, and Crush) are all
acceptable. All procedural complications and adverse events
will be recorded throughout the implant procedure.
Intravascular ultrasound. Intravascular ultrasound
will be performed after stent implantation and possible
postdilatation, as recommended.31,32 Postdilatation will
aim to achieve a minimum stent area of N8.5 mm2 in the
carina and N5.5 mm2 in the ostium of the left anterior
descending and circumflex arteries. The IVUS analyses
will be explorative and performed at the study sites
because these are not mandatory and not randomized.
Optical coherence tomography. Optical coherence
tomography is a catheter-based technology producing
ultra-high-resolution, cross-sectional, intravascular images
from backscattered infrared signals. It has a resolution of
5 to 20 μm, which is higher than IVUS and enables
optimal plaque identification, detection of thin tissue
structures (eg, reendothelialization, neointimal prolifera-
tion, and dissections), and visualization of stent struts.33
Baseline OCT will not be performed. Based on test runs
subject to quality control by the core laboratory and the
feasibility of performing the OCT protocol procedure in
the specified time frame, 5 sites have been selected to
perform post-PCI OCT at 3 months. Optical coherence
tomography of the stented region of the target vessel
including 5 mm proximal and distal will be performed in
100 patients. It will be performed with the St Jude
Lightlab C7 Dragonfly Imaging Catheter (St Paul, MN).
Optical coherence tomography analyses will be per-
formed by an independent core laboratory.
Follow-up period. Evaluation before discharge will be
performed andwill include the assessment of adverse events
andmedication aswell as an electrocardiogram. Patientswill
be followed up for a total of 60 months after PCI with
assessments at 3, 6, 12, 24, 36, 48, and 60 months (see
Figure). The assessments at 36, 48, and 60 months may be
conducted via telephone or (e-)mail. A 3-month follow-up,
coronary angiography andOCTwill be performed following
local protocols in a subset of 100 patients.
Study definitions
Baseline variables will include gender, age, height, weight,
complete medical history, all medication used up to 3
months before enrollment, and laboratory assessments.
Death will be considered cardiac unless an unequivocal
noncardiac cause can be established. Unwitnessed death
and death of unknown cause will be considered cardiac.
Death will be considered vascular when due to cerebro-
vascular disease, pulmonary embolism, ruptured aortic
aneurysm, aortic dissection, or any other vascular cause.
Death will be classified as noncardiovascular when the
cause is not covered by the above definitions (including
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or suicide). Myocardial infarction will be defined according
to the third universal definition, and periprocedural
myocardial infarction according to the Society for Cardio-
vascular Angiography and Interventions criteria.34,35 Defi-
nite, probable, and possible stent thrombosis and the
location of revascularizations will be adjudicated per the
Academic Research Consortium definitions.28 Bleeding will
be assessed in accordance with the BARC definitions.29
Statistical considerations
Statistical analyses. The trial will be powered for
noninferiority testing of the primary end point between
patients enrolled in the Synergy stent group with
short-duration DAPT vs the Xience stent group with
longer-duration DAPT. The primary analysis will be
performed at 24 months after the index procedure and
will be based on the principle of intention to treat.
Baseline characteristics will be compared between both
treatment groups using the Wilcoxon rank sum test or
analysis of variance test based on their distributions.
Categorical variables will be compared between groups
using the likelihood-ratio χ2 test or Fisher exact test.
Estimation of the cumulative MACE rate will be per-
formed using the Kaplan-Meier method and events
between treatment groups will be compared by the
log-rank test. Using a proportional hazards model, hazard
ratios with 95% CIs will be calculated as Synergy arm vs
Xience arm, with values N1 indicating increased hazard in
the Synergy arm. The proportionality assumptions will be
checked by visual estimation after plotting the log
cumulative hazard vs (log) time at follow-up after index
procedure and by applying a test for nonproportional
hazards using the Schoenfeld residuals.36 For secondary
end points, differences in absolute outcome values
(incidences) will be statistically tested between groups
by using Fisher exact test or Pearson χ2 test. Two-sided
95% CIs of the difference in percentages between
treatments will be calculated using exact methods.
Kaplan-Meier estimates and survival curves will be
displayed along with log-rank test results.
The effect measure is the risk difference expressed as
the difference in the MACE rate among patients
randomized to treatment with the Synergy stent to that
among patients treated with the Xience stent at
24 months. Noninferiority will be achieved if the upper
limit of the 1-sided 95% CI of the absolute risk difference
is less than the noninferiority margin of 7.5%. If
noninferiority has been established, superiority testing
will be performed, as well as calculation of 2-sided 95%
CIs, both applied to the intention-to-treat population.
Statistical analysis will be performed by Diagram B.V.
(Zwolle, the Netherlands) using SPSS 20.0 (SPSS, Chicago,
IL) or SAS 9.2 (SAS, Cary, NC). All statistical tests will be
interpreted at a 2-sided significance level of .05 and all CIs
at a 2-sided level of 95%.Sample size justification. The primary end point for
the study is the 24-month MACE rate, expressed as the
proportion of patients who experience MACE within
730 days after randomization. We anticipate a 20%
incidence of the primary end point in both groups. This
assumption is based on the 1- and 5-year major adverse
cardiac and cardiovascular event rates (15.8% and 36.9%)
of the SYNTAX left main substudy,2,5 the 18-month major
adverse cardiac and cardiovascular event rate (8.9% for an
everolimus-eluting stent and 10.8% for a sirolimus-eluting
stent) of the PRECOMBAT-2 study,4 the 1-year TVR rate
(19.6%) of “the Milan experience,”37 and the 2-year
combined end point of death and TVR (17.2%) of the
MAIN-COMPARE study.38 These studies compared PCI to
CABG for uLMCA treatment. Studies evaluating 2 different
stents for uLMCA treatment showed similar event rates.
The 2-year combined end point of death, MI, and TVR of
the ISAR-LEFT MAIN study was 21.3% for a
paclitaxel-eluting stent and 20.6% for a sirolimus-eluting
stent.39 In the ISAR-LEFT MAIN 2 study, the same end
point was 17.5% for a zotarolimus-eluting stent and 14.3%
for an everolimus-eluting stent after 1 year of follow-up.40
As such, for the IDEAL-LM trial, a 20% MACE rate at
2 years was considered realistic.
The primary objective of the trial is to establish the
noninferiority of the Synergy stent relative to the Xience
stent for prevention ofMACE. The effectmeasure is the risk
difference expressed as the difference in the MACE rate
among patients randomized to treatmentwith the Synergy
stent (index, r1) to that among patients randomized to
treatment with the Xience stent (control, r0). The null
hypothesis is that the risk difference (r1 − r0) is larger
than or equal to the specified noninferiority margin of
7.5%. The alternative hypothesis is that the difference in
the MACE rate is less than 7.5%. The null hypothesis of
inferiority of the Synergy stent to the Xience stent will be
rejected if the upper bound of 95% CI of risk difference
(r1 − r0) falls below 7.5%. With 409 patients per arm (a
total study population of 818 patients), the study has 85%
power to reject the null hypothesis of inferiority of the
Synergy stent to the Xience stent. The inclusion of 818
patients was completed on September 30 2016.Study organization and data management
Data collection/data management/record keep-
ing. The imaging analyses will be performed by an
independent core laboratory (Cardialysis, Rotterdam, the
Netherlands). A data safety monitoring board will be
appointed to assess the safety of the patients participating
in the study. Because blinding is not possible because of
differences in stent appearance and duration of DAPT, a
CEC will be appointed to adjudicate all clinical study end
point events. The clinical source documents will be
redacted in such a way that members of the CEC will be
unaware of the treatment arm the patient has been
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research organization that is responsible to provide
blinded data to the CEC. The sponsor reserves the right
to stop the study if this is the recommendation of the data
safety monitoring board and/or CEC.Summary
IDEAL-LM is a prospective, randomized, multicenter
study that will compare the 2-year efficacy and safety of
the novel Synergy stent followed by 4 months of DAPT to
the commonly used Xience stent followed by 12 months
of DAPT in patients with an indication for PCI of an
uLMCA. The study will provide novel insights into the
optimal treatment strategy for uLMCA disease (www.
clinicaltrials.gov NCT02303717).Disclosures
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